Essential Thrombocythemia Market In The 7MM Valued At USD 430 Million In 2025, Set To Grow At 12% CAGR Through 2036

(MENAFN- GlobeNewsWire - Nasdaq) Rising diagnosed prevalence (about 170,000 US cases in 2025), wider JAK2/CALR molecular testing and the 2026 FDA approval of ropeginterferon alfa-2b drive growth in ET treatment across the US, EU4, UK and Japan.

Dublin, Oct. 21, 2026 (GLOBE NEWSWIRE) -- "Essential Thrombocythemia - Market Insight, Epidemiology, and Market Forecast - 2036" has been added to ResearchAndMarkets.com's offering.

Essential Thrombocythemia Market Poised for Strong Growth as Targeted Therapies Advance

The essential thrombocythemia market is expected to expand significantly through 2036, supported by rising diagnosed prevalence, improved molecular testing, greater disease awareness, and the development of targeted and disease-modifying therapies. According to the report, the market across the United States, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan reached approximately USD 430 million in 2025. From 2026 to 2036, the market is projected to grow at a CAGR of approximately 12%.

The United States represented the largest regional market, generating approximately USD 265 million in 2025. Japan and Europe are also expected to record steady growth as diagnostic rates improve and advanced therapies gain wider adoption. The report provides historical and forecasted market analysis for 2022-2036, including patient burden, treatment patterns, therapy uptake, pricing, market access, and competitive dynamics across the seven major markets (7MM).

Essential Thrombocythemia Epidemiology and Patient Burden

Essential thrombocythemia primarily affects adults, with the highest patient share occurring among individuals aged over 60 years. Women account for approximately 65% of cases in the United States, compared with 35% among men. The median estimated survival is approximately 20 years, increasing to nearly 33 years for patients diagnosed before age 60.

Approximately 170,000 diagnosed prevalent cases were recorded in the United States in 2025, and the patient population is expected to increase through 2036. Of these cases, approximately 102,000 were symptomatic and 68,000 were asymptomatic. JAK2 mutations accounted for the largest mutation-specific population, representing approximately 92,000 US cases and exceeding CALR, MPL, and triple-negative subtypes.

Thrombosis remains the principal cause of morbidity and mortality, affecting approximately 20% of patients, while bleeding complications occur in about 10%. Japanese patients demonstrate a lower risk of thrombotic complications than Western populations, indicating that genetic background may influence clinical presentation and outcomes. Approximately 10% of patients may progress to post-essential thrombocythemia myelofibrosis.

Current Essential Thrombocythemia Treatment Landscape

Treatment is selected according to age, thrombosis history, mutation status, cardiovascular risk, platelet levels, and treatment tolerability. Low-risk patients may receive observation and low-dose Aspirin, while high-risk patients generally require cytoreductive therapy. Hydroxyurea remains the most frequently used first-line cytoreductive treatment, with Anagrelide, Busulfan, and interferon-based therapies used in selected patients or second-line settings.

In 2025, Anagrelide led the US essential thrombocythemia market with approximately 35% of therapy-specific revenue. Established treatments continue to support rapid platelet control, but resistance, intolerance, persistent thrombotic risk, and limited disease-modifying activity create demand for new options.

Peginterferon alfa-2a (PEGASYS) is approved specifically for essential thrombocythemia in Europe. In August 2024, Pharma& announced European Commission marketing authorization for PEGASYS as monotherapy for adults with essential thrombocythemia. In July 2025, the company announced UK authorization for adults with polycythemia vera or essential thrombocythemia.

Pipeline Innovation and Competitive Outlook

The essential thrombocythemia pipeline is shifting toward mechanism-based treatments designed to deliver durable hematologic and molecular responses. Development activity includes therapies targeting JAK-STAT signaling, interferon-mediated immune modulation, epigenetic regulation, abnormal megakaryopoiesis, and disease-driving mutations.

• Ropeginterferon alfa-2b (BESREMi): PharmaEssentia and AOP Orphan Pharmaceuticals are advancing this long-acting interferon therapy. The 2026 National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology recognize ropeginterferon alfa-2b-njft as a Category 1 preferred option for high-risk patients with inadequate response or loss of response to prior cytoreductive therapy.
• Bomedemstat: Merck is developing this lysine-specific demethylase 1 (LSD1) inhibitor as a potential disease-modifying treatment and is evaluating it in Phase III trials (Shorespan-006 and Shorespan-007).
• Pelabresib: Novartis is developing this bromodomain and extra-terminal (BET) inhibitor, which may contribute to the next generation of targeted therapies addressing underlying disease biology.
• INCA033989: Incyte is evaluating a mutation-directed approach for CALR-mutated disease, reflecting the broader transition toward precision medicine.

In January 2026, PharmaEssentia announced positive topline results from the Phase IIb EXCEED-essential thrombocythemia trial of ropeginterferon alfa-2b-njft. During the same month, the US Food and Drug Administration accepted the company's supplemental Biologics License Application for the treatment of adults with essential thrombocythemia. In August 2026, the FDA approved ropeginterferon alfa-2b-njft (BESREMi) for adults with essential thrombocythemia, the first new FDA approval in this indication in almost 30 years.

Leading companies covered in the competitive analysis include Pharma&, PharmaEssentia, AOP Orphan Pharmaceuticals, Merck, Novartis, and Incyte. The US launch of ropeginterferon alfa-2b and the expected entry of bomedemstat, pelabresib, and INCA033989 may intensify competition, support premium pricing, and accelerate movement away from conventional cytoreduction toward targeted and disease-modifying treatment.

Market Drivers and Unmet Needs

Growth in the essential thrombocythemia market is being driven by expanding molecular testing, increasing identification of asymptomatic patients, rising prevalence, and greater physician interest in long-acting therapies. Stronger clinical evidence for next-generation interferons, LSD1 inhibitors, BET inhibitors, and mutation-specific agents is also creating commercial opportunities.

Important unmet needs include diagnostic differentiation, underdiagnosis, treatment resistance or intolerance, persistent thrombosis despite therapy, long-term safety concerns, and the absence of curative options. The risk of progression to myelofibrosis or acute leukemia further reinforces the need for therapies that provide sustained disease control rather than platelet reduction alone.

Report Coverage and Strategic Value

The report evaluates essential thrombocythemia epidemiology, market size, treatment practices, pipeline development, drug uptake, pricing trends, patient share, and market access across the 7MM. It includes SWOT and conjoint analyses of emerging therapies based on efficacy, safety, administration frequency, route of administration, order of entry, probability of success, and addressable patient population.

Primary research incorporates insights from more than six key opinion leaders (KOLs) across the 7MM, including specialists connected with institutions such as the University of North Carolina at Chapel Hill, the University of Tokyo Hospital, and King's College London. These perspectives support analysis of prescribing patterns, treatment switching, adherence, accessibility, and clinical adoption.

Overall, the essential thrombocythemia market outlook remains favorable. Rising patient identification, regulatory progress including the 2026 US approval of ropeginterferon alfa-2b, and the anticipated launch of further first-in-class therapies are expected to support sustained market expansion through 2036 while creating opportunities for pharmaceutical companies, investors, healthcare providers, and market access stakeholders.

Key Topics Covered:
1. Key Insights
2. Report Introduction
3. Executive Summary
4. Key Events
4.1. Upcoming Key Catalysts
4.2. Key Transactions And Collaborations
4.3. News Flow
4.4. Key Conference Highlights
5. Epidemiology and Market Forecast Methodology
6. Essential Thrombocythemia Market Overview at a Glance
6.1. Clinical Landscape Analysis (By Phase, Molecule Type, and RoA)
6.2. Market Share (%) Distribution of Essential Thrombocythemia By Therapies in the 7MM, in 2025
6.3. Market Share (%) Distribution of Essential Thrombocythemia By Therapies in the 7MM, in 2036
7. Disease Background and Overview of Essential Thrombocythemia
7.1. Introduction
7.2. Types
7.3. Symptoms
7.4. Causes
7.5. Pathophysiology
7.6. Diagnosis
7.7. Treatment
8. Treatment Guidelines for Essential Thrombocythemia
9. Epidemiology and Patient Population of Essential Thrombocythemia
9.1. Key Findings
9.2. Assumptions and Rationale
9.3. Total Diagnosed Prevalent Cases of Essential Thrombocythemia in the 7MM
9.4. The United States
9.4.1. Total Diagnosed Prevalent Cases of Essential Thrombocythemia in the United States
9.4.2. Symptom-specific Diagnosed Prevalent Cases of Essential Thrombocythemia in the United States
9.4.3. Gender-specific Diagnosed Prevalent Cases of Essential Thrombocythemia in the United States
9.4.4. Mutation-specific Diagnosed Prevalent Cases of Essential Thrombocythemia in the United States
9.4.5. Risk-specific Diagnosed Prevalent Cases of Essential Thrombocythemia in the United States
9.4.6. Age-specific Diagnosed Prevalent Cases of Essential Thrombocythemia in the United States
9.4.7. Total Treated Cases of Essential Thrombocythemia in the United States
9.5. EU4 and the UK
9.5.1. Total Diagnosed Prevalent Cases of Essential Thrombocythemia in EU4 and the UK
9.5.2. Symptom-specific Diagnosed Prevalent Cases of Essential Thrombocythemia in EU4 and the UK
9.5.3. Gender-specific Diagnosed Prevalent Cases of Essential Thrombocythemia in EU4 and the UK
9.5.4. Mutation-specific Diagnosed Prevalent Cases of Essential Thrombocythemia in EU4 and the UK
9.5.5. Risk-specific Diagnosed Prevalent Cases of Essential Thrombocythemia in EU4 and the UK
9.5.6. Age-specific Diagnosed Prevalent Cases of Essential Thrombocythemia in EU4 and the UK
9.5.7. Total Treated Cases of Essential Thrombocythemia in EU4 and the UK
9.6. Japan
9.6.1. Total Diagnosed Prevalent Cases of Essential Thrombocythemia in Japan
9.6.2. Symptom-specific Diagnosed Prevalent Cases of Essential Thrombocythemia in Japan
9.6.3. Gender-specific Diagnosed Prevalent Cases of Essential Thrombocythemia in Japan
9.6.4. Mutation-specific Diagnosed Prevalent Cases of Essential Thrombocythemia in Japan
9.6.5. Risk-specific Diagnosed Prevalent Cases of Essential Thrombocythemia in Japan
9.6.6. Age-specific Diagnosed Prevalent Cases of Essential Thrombocythemia in Japan
9.6.7. Total Treated Cases of Essential Thrombocythemia in Japan
10. Patient Journey of Essential Thrombocythemia
11. Marketed Therapies
11.1. Marketed Competitive Landscape of Essential Thrombocythemia
11.2. Peginterferon alfa-2a (PEGASYS): Pharma&
11.2.1. Drug Description
11.2.2. Regulatory Milestones
11.2.3. Other Developmental Activities
11.2.4. Summary of Pivotal Trials
11.2.5. Clinical Development
11.2.5.1. Clinical Trial Information
11.2.6. Safety and Efficacy
11.2.7. Analyst's Views
12. Emerging Therapies
12.1. Emerging Competitive Landscape of Essential Thrombocythemia
12.2. Ropeginterferon alfa-2b (BESREMi): PharmaEssentia and AOP Orphan Pharmaceuticals
12.2.1. Drug Description
12.2.2. Other Developmental Activities
12.2.3. Clinical Development
12.2.3.1. Clinical Trials Information
12.2.4. Safety and Efficacy
12.2.5. Analyst's Views
12.3. Bomedemstat (MK-3543/IMG-7289): Merck
12.3.1. Drug Description
12.3.2. Other Developmental Activity
12.3.3. Clinical Development
12.3.3.1. Clinical Trials Information
12.3.4. Safety and Efficacy
12.3.5. Analyst's Views
13. Essential Thrombocythemia: 7MM Analysis
13.1. Key Findings
13.2. Market Outlook of Essential Thrombocythemia
13.3. Key Market Forecast Assumptions
13.3.1. Cost Assumptions
13.3.2. Pricing Trends
13.3.3. Analogue Assessment
13.3.4. Launch Year and Therapy Uptakes
13.4. Conjoint Analysis of Essential Thrombocythemia
13.5. Total Market Size of Essential Thrombocythemia in the 7MM
13.6. Total Market Size of Essential Thrombocythemia by Therapies in the 7MM
13.7. The United States
13.7.1. Total Market Size of Essential Thrombocythemia in the United States
13.7.2. Total Market Size of Essential Thrombocythemia by Therapies in the United States
13.8. EU4 and the UK
13.8.1. Total Market Size of Essential Thrombocythemia in EU4 and the UK
13.8.2. Total Market Size of Essential Thrombocythemia by Therapies in EU4 and the UK
13.9. Japan
13.9.1. Total Market Size of Essential Thrombocythemia in Japan
13.9.2. Total Market Size of Essential Thrombocythemia by Therapies in Japan
14. Unmet Needs of Essential Thrombocythemia
15. SWOT Analysis of Essential Thrombocythemia
16. KOL Views of Essential Thrombocythemia
17. Market Access and Reimbursement of Essential Thrombocythemia
17.1. The United States
17.2. EU4 and the UK
17.2.1. Germany
17.2.2. France
17.2.3. Italy
17.2.4. Spain
17.2.5. United Kingdom
17.3. Japan
17.4. Summary and comparison of Market Access and Pricing Policy Developments in 2025
17.5. Market Access and Reimbursement of Essential Thrombocythemia Therapies
18. Appendix
18.1. Bibliography
18.2. Report Methodology
19. Analyst's Capabilities
20. Disclaimer
21. About the Publisher
List of Tables [41]
List of Figures [47]
A selection of companies mentioned in this report includes, but is not limited to:

• Pharma&
• PharmaEssentia
• AOP Orphan Pharmaceuticals
• Merck
• Novartis
• Incyte

For more information about this report visit

About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

CONTACT: CONTACT: ResearchAndMarkets.com Laura Wood,Senior Press Manager... For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900

MENAFN21102026004107003653ID1111842805